Form 4: Teladoc Health Executive Daniel Trencher Reports Stock Transactions
SEC Form 4 Filing
Daniel Trencher, Chief Strategy Officer of Teladoc Health, reports the acquisition and disposal of common stock and derivative securities related to performance stock units and restricted stock units.
Summary
- On May 31, 2024, Daniel Trencher, Chief Strategy Officer of Teladoc Health, engaged in transactions involving Teladoc Health's common stock.
- These transactions included the conversion of performance stock units and restricted stock units into common stock.
- Specifically, 951 shares were acquired through the conversion of performance stock units, and 1,179 and 2,790 shares were acquired through the conversion of restricted stock units.
- On June 3, 2024, Trencher sold 1,790 shares of common stock at a price of $11.157 per share.
- These sales were likely to cover tax withholding obligations related to the vesting of the stock units.
- Following these transactions, Trencher directly owns 28,322 shares of Teladoc Health common stock and holds derivative securities including 6,657 performance stock units, 3,538 restricted stock units from a 2022 grant, and 19,532 restricted stock units from a 2023 grant.
Sentiment
Score: 5
Explanation: The sentiment is neutral as it simply reports stock transactions by an executive, which is a routine occurrence. The sales are likely to cover tax obligations, not necessarily indicative of a negative outlook.
Industry Context
Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track management's sentiment and actions regarding their company's stock.
Comparison to Industry Standards
- Tracking insider transactions is a common practice in financial analysis.
- Comparing Trencher's transactions to those of other executives at Teladoc and similar companies (e.g., Amwell, Livongo before its acquisition) can provide insights into the overall sentiment and expectations of company leadership.
- Analyzing the timing and volume of these transactions relative to company performance and industry trends can further inform investment decisions.
Stakeholder Impact
- The transactions may have a minor impact on shareholders by slightly increasing the supply of shares in the market.
- The transactions reflect the executive's compensation structure, which includes stock-based awards.
Key Dates
| Date | Description |
|---|---|
| 03/01/2022 | Reporting person was granted 14,149 restricted stock units, vesting one-third on the first anniversary of the grant date, with the remainder vesting in eight substantially equal quarterly installments thereafter. |
| 03/03/2023 | Reporting person was granted 33,482 restricted stock units, vesting one-third on March 1, 2024, with the remainder vesting in eight substantially equal quarterly installments thereafter. |
| 03/01/2024 | The reporting person earned 11,411 performance stock units, vesting one-third on March 1, 2024, with the remainder vesting in eight substantially equal quarterly installments thereafter. |
| 05/31/2024 | Conversion of performance stock units and restricted stock units into common stock. |
| 06/03/2024 | Sale of 1,790 shares of common stock at $11.157 per share. |
| 06/04/2024 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.